AbstractDihydroartemisinin (DHA), an active metabolite of artemisinin derivatives, is the most remarkable anti-malarial drug and has little toxicity to humans. Recent studies have shown that DHA effectively inhibits the growth of cancer cells. In the present study, we intended to elucidate the mechanisms underlying the inhibition of growth of iron-loaded human myeloid leukemia K562 cells by DHA. Mitochondria are important regulators of both autophagy and apoptosis, and one of the triggers for mitochondrial dysfunction is the generation of reactive oxygen species (ROS). We found that the DHA-induced autophagy of leukemia K562 cells, whose intracellular organelles are primarily mitochondria, was ROS dependent. The autophagy of these cells was...
Withaferin A (WA), a promising anticancer constituent of Ayurvedic medicinal plant Withania somnifer...
Dihydroartemisinin (DHA) has been globally recognized for its efficacy and safety in the clinical tr...
<div><p>Despite recent advances in the therapy of non-small cell lung cancer (NSCLC), the chemothera...
AbstractDihydroartemisinin (DHA), an active metabolite of artemisinin derivatives, is the most remar...
Dihydroartemisinin (DHA), an active metabolite and derivative of artemisinin, is the most effective ...
Thesis (Master's)--University of Washington, 2015Artemisinin generates cytotoxic free radicals when ...
<div><p>Artemisinin and its main active metabolite dihydroartemisinin, clinically used antimalarial ...
Dihydroartemisinin (DHA), a front-line antimalarial herbal compound, has been shown to possess promi...
Artemisinin and its main active metabolite dihydroartemisinin, clinically used antimalarial agents w...
Background: Dihydroartemisinin (DHA) is a semisynthetic derivative of artemisinin and has antiprolif...
Dihydroartemisinin (DHA), a semi-synthetic derivative of artemisinin, has recently shown antitumor a...
Dihydroartemisinin (DHA), a semi-synthetic derivative of artemisinin, has recently shown antitumor a...
Cholangiocarcinoma (CCA) is a very aggressive cancer arising from the malignant transformation of c...
Cholangiocarcinoma (CCA) is a very aggressive cancer arising from the malignant transformation of c...
Abstract Background Dihydroartemisinin (DHA), a semi-synthetic derivative of artemisinin, isolated f...
Withaferin A (WA), a promising anticancer constituent of Ayurvedic medicinal plant Withania somnifer...
Dihydroartemisinin (DHA) has been globally recognized for its efficacy and safety in the clinical tr...
<div><p>Despite recent advances in the therapy of non-small cell lung cancer (NSCLC), the chemothera...
AbstractDihydroartemisinin (DHA), an active metabolite of artemisinin derivatives, is the most remar...
Dihydroartemisinin (DHA), an active metabolite and derivative of artemisinin, is the most effective ...
Thesis (Master's)--University of Washington, 2015Artemisinin generates cytotoxic free radicals when ...
<div><p>Artemisinin and its main active metabolite dihydroartemisinin, clinically used antimalarial ...
Dihydroartemisinin (DHA), a front-line antimalarial herbal compound, has been shown to possess promi...
Artemisinin and its main active metabolite dihydroartemisinin, clinically used antimalarial agents w...
Background: Dihydroartemisinin (DHA) is a semisynthetic derivative of artemisinin and has antiprolif...
Dihydroartemisinin (DHA), a semi-synthetic derivative of artemisinin, has recently shown antitumor a...
Dihydroartemisinin (DHA), a semi-synthetic derivative of artemisinin, has recently shown antitumor a...
Cholangiocarcinoma (CCA) is a very aggressive cancer arising from the malignant transformation of c...
Cholangiocarcinoma (CCA) is a very aggressive cancer arising from the malignant transformation of c...
Abstract Background Dihydroartemisinin (DHA), a semi-synthetic derivative of artemisinin, isolated f...
Withaferin A (WA), a promising anticancer constituent of Ayurvedic medicinal plant Withania somnifer...
Dihydroartemisinin (DHA) has been globally recognized for its efficacy and safety in the clinical tr...
<div><p>Despite recent advances in the therapy of non-small cell lung cancer (NSCLC), the chemothera...